<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03840902</url>
  </required_header>
  <id_info>
    <org_study_id>MS200647_0005</org_study_id>
    <secondary_id>2018-003265-34</secondary_id>
    <nct_id>NCT03840902</nct_id>
  </id_info>
  <brief_title>M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>A Multicenter, Double Blind, Randomized, Controlled Study of M7824 With Concurrent Chemoradiation Followed by M7824 Versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants With Unresectable Stage III Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMD Serono Research &amp; Development Institute, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>EMD Serono</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate safety and efficacy in participants treated
      with concomitant chemoradiation therapy (cCRT) plus M7824 followed by M7824 compared to cCRT
      plus placebo followed by durvalumab.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 16, 2019</start_date>
  <completion_date type="Anticipated">January 26, 2028</completion_date>
  <primary_completion_date type="Anticipated">March 4, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) Assessed by Independent Review Committee (IRC)</measure>
    <time_frame>Time from first dose up to 59 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Treatment Emergent Adverse Events (TEAEs) and Treatment-related AEs</measure>
    <time_frame>Baseline up to 8.8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Baseline up to 8.8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from Baseline in Diffusing Capacity of Lung for Carbon Monoxide (DLCO)</measure>
    <time_frame>Baseline up to 14 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Programmed death-ligand 1 (PD-L1) Expression in Tumors Assessed with Immunohistochemistry (IHC) and Association with Efficacy</measure>
    <time_frame>Baseline up to 8.8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response According to RECIST 1.1 Assessed by IRC</measure>
    <time_frame>Baseline up to 8.8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response According to RECIST 1.1</measure>
    <time_frame>Baseline up to 8.8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of M7824 as Measured by Antidrug Antibody (ADA) Assays</measure>
    <time_frame>Baseline up to 8.8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration Immediately Before Next Dosing (Ctrough)</measure>
    <time_frame>Baseline up to 14 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration Immediately at End of Infusion (Ceoi)</measure>
    <time_frame>Baseline up to 14 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from Baseline in High-resolution Computed Tomography (HRCT)</measure>
    <time_frame>Baseline up to 14 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from Baseline in Forced Expiratory Volume in one Second (FEV1)</measure>
    <time_frame>Baseline up to 14 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from Baseline in Forced Vital Capacity (FVC)</measure>
    <time_frame>Baseline up to 14 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from Baseline in 6-minutes Walking Test</measure>
    <time_frame>Baseline up to 14 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 1: cCRT plus M7824 followed by M7824</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive cCRT: Cisplatin/Etoposide or Carboplatin/Paclitaxel or Cisplatin/Pemetrexed concomitant with Intensity Modulated Radiation Therapy (IMRT) along with M7824 followed by M7824.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: cCRT plus placebo followed by durvalumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive cCRT: Cisplatin/Etoposide or Carboplatin/Paclitaxel or Cisplatin/Pemetrexed concomitant with Intensity Modulated Radiation Therapy (IMRT) along with placebo matched to M7824 followed by durvalumab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M7824</intervention_name>
    <description>Participants will receive intravenous infusion of 1200 milligram (mg) M7824 over 1 hour every 2 weeks (q2w) during cCRT and up to 1 year after cCRT until unacceptable toxicity, confirmed disease progression assessed by investigator.</description>
    <arm_group_label>Arm 1: cCRT plus M7824 followed by M7824</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive intravenous infusion of placebo matched to M7824 over 1 hour q2w during cCRT until unacceptable toxicity, confirmed disease progression assessed by investigator.</description>
    <arm_group_label>Arm 2: cCRT plus placebo followed by durvalumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <description>Participants will receive intravenous infusion of durvalumab 10 milligram per kilogram (mg/Kg) over 1 hour q2w up to 1 year after cCRT until unacceptable toxicity, confirmed disease progression assessed by investigator.</description>
    <arm_group_label>Arm 2: cCRT plus placebo followed by durvalumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Participants will receive etoposide 50 mg/m^2 intravenously over a minimum of 30 minutes up to 60 minutes daily on Day 1 to 5 and Day 29 to 33 during cCRT.</description>
    <arm_group_label>Arm 1: cCRT plus M7824 followed by M7824</arm_group_label>
    <arm_group_label>Arm 2: cCRT plus placebo followed by durvalumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>Participants will receive pemetrexed at a dose of 500 mg/m^2 intravenously over 10 minutes or according to local standards on Days 1, 22, and 43 during cCRT.</description>
    <arm_group_label>Arm 1: cCRT plus M7824 followed by M7824</arm_group_label>
    <arm_group_label>Arm 2: cCRT plus placebo followed by durvalumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Participants will receive carboplatin intravenously based on area under curve (AUC) 2 over 30 minutes on Day 1, Day 8, Day 15, Day 22, Day 29, Day 36, and Day 43 during cCRT.</description>
    <arm_group_label>Arm 1: cCRT plus M7824 followed by M7824</arm_group_label>
    <arm_group_label>Arm 2: cCRT plus placebo followed by durvalumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Participants will receive paclitaxel intravenously at a dose of 45 mg/m^2 over 60 minutes on Day 1, Day 8, Day 15, Day 22, Day 29, Day 36, and Day 43 during cCRT.</description>
    <arm_group_label>Arm 1: cCRT plus M7824 followed by M7824</arm_group_label>
    <arm_group_label>Arm 2: cCRT plus placebo followed by durvalumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>In combination with etoposide, participants will receive cisplatin 50 mg/m^2 intravenously over 60 minutes on Days 1, 8, 29, and 36 during cCRT. In combination with pemetrexed, participants will receive cisplatin 75 mg/m2 intravenously over 60 minutes on Days 1, 22, and 43 during cCRT.</description>
    <arm_group_label>Arm 1: cCRT plus M7824 followed by M7824</arm_group_label>
    <arm_group_label>Arm 2: cCRT plus placebo followed by durvalumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intensity Modulated Radiation Therapy (IMRT)</intervention_name>
    <description>Participants will receive IMRT 5 fractions per week for about 6 weeks (Total 60 gray [Gy]).</description>
    <arm_group_label>Arm 1: cCRT plus M7824 followed by M7824</arm_group_label>
    <arm_group_label>Arm 2: cCRT plus placebo followed by durvalumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants must have histologically documented NSCLC who present with Stage III
             locally advanced, unresectable disease (International Association for the Study of
             Lung Cancer Staging Manual in Thoracic Oncology

          -  Participants with tumor harboring an Epidermal growth factor receptor (EGFR)
             sensitizing (activating) mutation, Anaplastic lymphoma kinase (ALK) translocation,
             ROS-1 rearrangement are eligible.

          -  Participants must have adequate pulmonary function defined as a forced expiratory
             volume in 1 second (FEV1) greater than equals to (&gt;=) 1.2 liters or &gt;= 50% of
             predicted normal volume measured within 3 weeks prior to randomization.

          -  Adequate hematological, hepatic and renal function as defined in the protocol

          -  Contraceptive use by males or females will be consistent with local regulations on
             contraception methods for those participating in clinical studies

        Exclusion Criteria:

          -  Participants with Mixed small cell with non-small cell lung cancer histology

          -  Recent major surgery within 4 weeks prior to entry into the study

          -  Significant acute or chronic infections including human immunodeficiency virus (HIV)
             or known acquired immunodeficiency syndrome, Active hepatitis B virus (HBV) or
             hepatitis C virus (HCV) infection and active tuberculosis

          -  Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness
             requiring hospitalization

          -  Active autoimmune disease that has required systemic treatment in past 1 year (i.e.,
             with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs)

          -  Any prior systemic cytotoxic chemotherapy for their NSCLC or any antibody or drug
             targeting T-cell coregulatory proteins
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>Merck KGaA, Darmstadt, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US Medical Information</last_name>
    <phone>888-275-7376</phone>
    <email>eMediUSA@emdserono.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Communication Center</last_name>
    <phone>+49 6151 72 5200</phone>
    <email>service@emdgroup.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California Irvine Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>zhuvw@uci.edu</email>
    </contact>
    <investigator>
      <last_name>Viola W Zhu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA Hematology Oncology - Main Site - 2020 Santa Monica</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>egaron@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Edward Garon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Health - Memorial Hospital - Memorial Hospital</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>robert.hoyer@uchealth.org</email>
    </contact>
    <investigator>
      <last_name>Robert Hoyer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lynn Cancer Institute Center</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>hrichter@brrh.com</email>
    </contact>
    <investigator>
      <last_name>Harold Richter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Holy Cross Hospital - Michael and Dianne Bienes CCC</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>david.drew@holy-cross.com</email>
    </contact>
    <investigator>
      <last_name>David Z Drew</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sylvester Comprehensive Cancer Center - University of Miami Health System</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>glopes@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Gilberto de Lima Lopes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>cbestvina@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Christine Bestvina</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>American Health Network of Indiana, LLC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>sridhar_boll@ahni.com</email>
    </contact>
    <investigator>
      <last_name>Sridhar R Bolla</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baptist Health Lexington Oncology Associates</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>firas.badin@bhsi.com</email>
    </contact>
    <investigator>
      <last_name>Firas Badin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland - DUPLICATE/Pediatric Surgery</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>christian.rolfo@umm.edu</email>
    </contact>
    <investigator>
      <last_name>Christian Rolfo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>mansfield.aaron@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Aaron S Mansfield</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>bh2682@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Brian S Henick</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Center of Nyack Hospital</name>
      <address>
        <city>Nyack</city>
        <state>New York</state>
        <zip>10960</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>lees@montefiorenyack.org</email>
    </contact>
    <investigator>
      <last_name>Sung Ho Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>FirstHealth of the Carolinas, Inc.</name>
      <address>
        <city>Pinehurst</city>
        <state>North Carolina</state>
        <zip>28374</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ckuzma@firsthealth.org</email>
    </contact>
    <investigator>
      <last_name>Charles S Kuzma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The James Cancer Hospital and Solove Research Institute</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>karl.haglund@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Karl E Haglund</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>villaruzl@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Liza C Villaruz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center - Unit 432 Thoracic Head and Neck Medical Oncology</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>astsao@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Anne Tsao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Polivalente de Asistencia e Inv. Clinica CER</name>
      <address>
        <city>San Juan</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>puigjuanmanuel@yahoo.com.ar</email>
    </contact>
    <investigator>
      <last_name>Juan Manuel Puig</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bendigo Hospital</name>
      <address>
        <city>Bendigo</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>sng@bendigohealth.org.au</email>
    </contact>
    <investigator>
      <last_name>Say L Ng</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Townsville Hospital</name>
      <address>
        <city>Douglas</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>suresh.varma@health.qld.gov.au</email>
    </contact>
    <investigator>
      <last_name>Suresh Varma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Calvary Central Districts Hospital</name>
      <address>
        <city>Elizabeth Vale</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>r.joshi@aoah.com.au</email>
    </contact>
    <investigator>
      <last_name>Rohit Joshi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital Melbourne - PARENT</name>
      <address>
        <city>Fitzroy</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>melissa.moore@svha.org.au</email>
    </contact>
    <investigator>
      <last_name>Melissa Moore</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Austin Health</name>
      <address>
        <city>Heidelberg Heights</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>whitesh1@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Shane White</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion Pergamino SA</name>
      <address>
        <city>Pergamino</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>susanakahl@yahoo.com.ar</email>
    </contact>
    <investigator>
      <last_name>Susana Kahl</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Randwick</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>craig.lewis@health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Craig Lewis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunshine Hospital</name>
      <address>
        <city>St Albans</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>sng@bendigohealth.org.au</email>
    </contact>
    <investigator>
      <last_name>Dishan Herath</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South West Healthcare - South West Oncology</name>
      <address>
        <city>Warrnambool</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>thayes@swarh.vic.gov.au</email>
    </contact>
    <investigator>
      <last_name>Theresa Hayes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>johan.vansteenkiste@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Johan Vansteenkiste</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Mont-Godinne</name>
      <address>
        <city>Yvoir</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>sebahat.ocak@uclouvain.be</email>
    </contact>
    <investigator>
      <last_name>Sebahat Ocak</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HGB - Hospital Giovanni Battista - Mãe de Deus Center - Centro de Pesquisa Clínica - Instituto do Câncer</name>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>alanazambuja@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Alan Azambuja</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital São Lucas da PUCRS</name>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>carlos.barrios@cpors.com</email>
    </contact>
    <investigator>
      <last_name>Carlos Henrique Escosteguy Barrios</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A. C. Camargo Cancer Center - Fundação Antônio Prudente</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>aelano.freitas@accamargo.org.br</email>
    </contact>
    <investigator>
      <last_name>Helano Freitas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BC Cancer Agency Center for the Southern Interior</name>
      <address>
        <city>Kelowna</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>staylor10@bccancer.bc.ca</email>
    </contact>
    <investigator>
      <last_name>Sara Taylor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Olomouc - Dept of Onkologicka klinika</name>
      <address>
        <city>Olomouc</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>bohuslav.melichar@fnol.cz</email>
    </contact>
    <investigator>
      <last_name>Bohuslav Melichar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nippon Medical School Hospital - Dept of Respiratory Medicine</name>
      <address>
        <city>Bunkyo-ku</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>kkubota@nms.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Kaoru Kubota</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital - Dept of Respiratory Medicine</name>
      <address>
        <city>Bunkyo-ku</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>yhosomi@cick.jp</email>
    </contact>
    <investigator>
      <last_name>Yukio Hosomi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saitama Medical University International Medical Center - Dept of Respiratory Medicine</name>
      <address>
        <city>Hidaka-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>kagamu19@saitama-med.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Hiroshi Kagamu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East - Dept of Respiratory Medicine</name>
      <address>
        <city>Kashiwa-shi</city>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>yzenken@cick.jp</email>
    </contact>
    <investigator>
      <last_name>Yoshitaka Zenke</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kobe City Hospital Organization Kobe City Medical Center General Hospital - Dept of Respiratory Medicine</name>
      <address>
        <city>Kobe-shi</city>
        <zip>650-0047</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ktomii@kcho.jp</email>
    </contact>
    <investigator>
      <last_name>Keisuke Tomii</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Institute Hospital of JFCR - Dept of Respiratory Medicine</name>
      <address>
        <city>Koto-ku</city>
        <zip>135-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>mnishio@jfcr.or.jp</email>
    </contact>
    <investigator>
      <last_name>Makoto Nishio</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kurume University Hospital - Dept of Lung Cancer Center</name>
      <address>
        <city>Kurume-shi</city>
        <zip>830-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ishii_hidenobu@med.kurume-u.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Hidenobu Ishii</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aichi Cancer Center Hospital - Dept of Respiratory Medicine</name>
      <address>
        <city>Nagoya-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>107974@aichi-cc.jp</email>
    </contact>
    <investigator>
      <last_name>Toyoaki Hida</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Osaka Medical Center for Cancer and Cardiovascular Diseases</name>
      <address>
        <city>Osaka-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>torukumagai@ybb.ne.jp</email>
    </contact>
    <investigator>
      <last_name>Toru Kumagai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kindai University Hospital (13859)</name>
      <address>
        <city>Osakasayama-shi</city>
        <zip>589-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>hidet31@med.kindai.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Hidetoshi Hayashi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shizuoka Cancer Center</name>
      <address>
        <city>Sunto-gun</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>t.takahashi@scchr.jp</email>
    </contact>
    <investigator>
      <last_name>Toshiaki Takahashi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kanagawa Cancer Center - Dept of Respiratory Medicine</name>
      <address>
        <city>Yokohama-shi</city>
        <zip>241-8515</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>katote@kcch.jp</email>
    </contact>
    <investigator>
      <last_name>Terufumi Kato</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>kupark@dsmc.or.kr</email>
    </contact>
    <investigator>
      <last_name>Keon UK Park</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>jslee0918@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jong-Seok Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>leedaeho@amc.seoul.kr</email>
    </contact>
    <investigator>
      <last_name>Dae Ho Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>shinsw@kumc.or.kr</email>
    </contact>
    <investigator>
      <last_name>Sang-Won Shin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>cbc1971@yuhs.ac</email>
    </contact>
    <investigator>
      <last_name>Byoung Chul Cho</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>Oncologykang@naver.com</email>
    </contact>
    <investigator>
      <last_name>Jin-Hyoung Kang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jeroen Bosch Ziekenhuis</name>
      <address>
        <city>'s Hertogenbosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>b.biesma@jbz.nl</email>
    </contact>
    <investigator>
      <last_name>Bonne Biesma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amphia Ziekenhuis - PARENT - Parent</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>leestk@amphia.nl</email>
    </contact>
    <investigator>
      <last_name>Kornelis van der Leest</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Martini ziekenhuis</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>w.jacobs@mzh.nl</email>
    </contact>
    <investigator>
      <last_name>Wouter J Jacobs</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Antonius Ziekenhuis - Dept Pulmonology - Nieuwegein</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>l.kastelijn1@antoniusziekenhuis.nl</email>
    </contact>
    <investigator>
      <last_name>Lisanne L Kastelijn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ISALA Klinieken Locatie Sophia</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>j.a.stigt@isala.nl</email>
    </contact>
    <investigator>
      <last_name>J.A. Stigt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar - Servicio de Oncologia</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>earriola@parcdesalutmar.cat</email>
    </contact>
    <investigator>
      <last_name>Edurne Aperribay</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron - Dept of Oncology</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>alex.martinez@vhebron.net</email>
    </contact>
    <investigator>
      <last_name>Alex Martinez Marti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICO l´Hospitalet - Hospital Duran i Reynals - Servicio de Oncologia</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ernestnadal@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ernest Nadal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario HM Madrid Sanchinarro - Servicio de Oncologia</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>bjimenez@hmhospitales.com</email>
    </contact>
    <investigator>
      <last_name>Beatriz Jimenez Munarriz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre - Servicio de Oncologia</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>lpazaresr@seom.org</email>
    </contact>
    <investigator>
      <last_name>Luis Paz-Ares Rodriguez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro Majadahonda</name>
      <address>
        <city>Majadahonda</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>mprovencio.ensayosclinicos@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Mariano Pulla</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>mmorenoji@unav.es</email>
    </contact>
    <investigator>
      <last_name>Marta Moreno</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Nuestra Señora de Valme - Servicio de Oncologia</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>valmeoncologia@yahoo.es</email>
    </contact>
    <investigator>
      <last_name>Jose Pradera</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio - Servicio de Oncologia</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>miriamag3@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Miriam Garcia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena - Servicio de Oncologia</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>dvicentebaz@yahoo.es</email>
    </contact>
    <investigator>
      <last_name>David Vicente Baz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia - Servicio de Hematologia y Oncologia Medica</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ameliainsamolla@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Amelia Molla</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>jonyin@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Tsung-Ying Yang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chi Mei Medical Center, Liou Ying</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>huangwentsung@mac.com</email>
    </contact>
    <investigator>
      <last_name>Wen-Tsung Huang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>chihyang@ntu.edu.tw</email>
    </contact>
    <investigator>
      <last_name>Chih-Hsin Yang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>sonice3982@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Chih-Feng Chian</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <link>
    <url>https://www.intrapidclinicaltrials.com/en</url>
    <description>INTR@PID Clinical Trial Program</description>
  </link>
  <link>
    <url>https://clinicaltrials.emdgroup.com/en/trial-details/?id=MS200647_0005</url>
    <description>Trial Awareness and Transparency website</description>
  </link>
  <link>
    <url>https://medical.emdserono.com/en_US/home.html</url>
    <description>US Medical Information website, Medical Resources</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>February 12, 2019</study_first_submitted>
  <study_first_submitted_qc>February 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2019</study_first_posted>
  <last_update_submitted>June 29, 2020</last_update_submitted>
  <last_update_submitted_qc>June 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-small Cell Lung Cancer</keyword>
  <keyword>Bintrafusp alfa (proposed INN)</keyword>
  <keyword>M7824</keyword>
  <keyword>Durvalumab</keyword>
  <keyword>Stage III</keyword>
  <keyword>INTR@PID LUNG 005</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Durvalumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Per company policy, following approval of a new product or a new indication for an approved product in both the EU and the US, EMD Serono will share study protocols, anonymized patient level and study level data and redacted clinical study reports from clinical trials in patients with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website https://www.emdgroup.com/en/research/our-approach-to-research-and-development/healthcare/clinical-trials/commitment-responsible-data-sharing.html</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

